| Cas No.: | 1392116-14-1 |
| 名称: | 2S-[[[(4S)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazol-1-yl][[(4-chlorophenyl)sulfonyl]amino]methylene]amino]-3-methyl-butanamide |
| 别名: | JD 5037,JD-5037 |
| SMILES: | ClC(C=C1)=CC=C1C2=NN(/C(N[C@@H](C(C)C)C(N)=O)=N/S(C3=CC=C(Cl)C=C3)(=O)=O)C[C@@H]2C4=CC=CC=C4 |
| 分子式: | C27H27Cl2N5O3S |
| 分子量: | 572.5 |
| 纯度: | |
| 保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | |
| In Vivo: | |
| In Vitro: | |
| References: | JD5037 is an inverse agonist of peripheral cannabinoid 1 (CB1) receptors (Ki = 0.35 nM).It displays >700-fold selectivity for CB1 over CB2, >1,000-fold selectivity over a panel of 70 receptors, transporters, and ion channels, and low blood-brain barrier penetrance.JD5037 is orally bioavailable and reduces food intake, body weight, and hormonal/metabolic abnormalities in diet-induced obese mice.JD5037 reverses hyperphagia, reduces body weight, and improves metabolic parameters in Magel2-null mice, a model of Prader-Willi syndrome. |
| Kinase Assay: | |
| Cell Assay: | |
| Animal Administration: | |
| References: |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
